Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRL3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,043
Award facts
- Contract value 100% obligated
- $34,042.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $34,042.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120 count). This firm fixed-price delivery order, awarded on November 28, 2025, with completion scheduled for December 1, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group is a registered federal contractor since 2001 specializing in distributing comprehensive pharmaceutical products and medical consumables to Department of Defense facilities.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy established to support recurring medical supply needs of military healthcare facilities worldwide. The parent IDC, designated SPE2DR and awarded on November 13, 2025, carries a $499.9 billion ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. Under this framework, DMS Pharmaceutical Group serves as a critical regional prime vendor contractor authorized to fulfill diverse pharmaceutical requirements including branded and generic prescription drugs, biologics, and medical consumables for Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FCRL3?
SPE2DR26FCRL3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 28, 2025.
How much is contract SPE2DR26FCRL3 worth?
The government has obligated $34,043 on SPE2DR26FCRL3.
Is contract SPE2DR26FCRL3 an order under another contract?
Yes. SPE2DR26FCRL3 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRL3 competed?
The extent of competition for SPE2DR26FCRL3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award